StockpollyBeta
Get App
Delisting riskPopularity #3,943
HOWL · NASDAQ · Biotechnology

Werewolf Therapeutics (HOWL)

Develops conditionally activated cytokine and T-cell-engager therapies for cancer.

$0.9742
vs last close−0.01 (−0.79%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue6211000000021
Cost of revenue000000000002
Gross profit5101000000019
1514172017201817169910
Research & development111013151316131312786
445455544258
Selling & marketing000000000000
General & administrative455555544258
Other expenses0000000000−5−4
Operating income−9−13−17−19−17−20−18−18−16−9−99
11120000−11−5−5
Interest income222221111100
Interest expense111111111110
Other non-operating income0−2−2−3−2−1−1−1−1−230
Income before tax−8−12−16−17−17−20−18−18−16−8−144
Net income from continuing operations−8−12−16−17−17−20−18−18−16−8−144
Net income−8−12−16−17−17−20−18−18−16−8−144
EPS, basic−$0.23−$0.33−$0.39−$0.40−$0.38−$0.46−$0.40−$0.40−$0.36−$0.17−$0.28$0.08
EPS, diluted−$0.23−$0.33−$0.39−$0.40−$0.38−$0.46−$0.40−$0.40−$0.36−$0.17−$0.28$0.08
Weighted average shares, basic363742444444454545464949
Weighted average shares, diluted363742444444454546474949
EBITDA−9−10−15−16−15−19−16−16−15−7−1211
Depreciation & amortization000000000002
EBIT−9−11−15−16−15−19−17−17−15−7−129